Do we really need to clarify that 90% of our accounts are currently active?

2022

Deeply honoured to be leading Europe’s emerging 10 medical translation companies as per Healthcare Business Review (Europe Special edition – July 25, 2022)

2019

Localisation of the Recommendations for a Global Curriculum in Medical Oncology, edition 2016, commissioned by the HESMO (Greek branch of the ESMO)

2018

*Linguistic validation of PRO questionnaire (full translation/validation cycle using independent processes and integrated approach)

2017

*Primary translation/localisation vendor for a UK, top-10 pharmaceutical company

*Primary translation/localisation vendor for a leading Greek CRO company

2016

*Language consultant for a major US pharmaceutical localisation agency

2015

*On-site, front-line language services during an FDA clinical trial inspection

2014

*On-site, front-line language services during an EMA clinical trial inspection

*Contract expansion to include the entire group of companies of a Swiss, top-3 pharmaceutical company

2011

*Language Lead on translation lifecycle for EMA submissions for a major EU localisation agency

*Primary translation/localisation vendor for a Swiss, top-3 pharmaceutical company

2010

*Primary translation/localisation vendor for a leading Greek CRO company

2009

*Primary translation/localisation vendor for an Italian, top-50 pharmaceutical company

2008

*Primary translation/localisation vendor for a Danish, top-20 pharmaceutical company

*Primary translation/localisation vendor for a US, top-5 pharmaceutical company

*Primary translation/localisation vendor for a Greek leading pharma advertising agency

2007

*Primary translation/localisation vendor for a Swiss, top-3 pharmaceutical company

*Primary translation/localisation vendor for a Swiss, top-50 pharmaceutical company

2005

*Full localisation cycle of a disease awareness campaign for a US, top-15 pharmaceutical company